Compare ADMA Biologics Inc (ADMA) vs American Well Corp (AMWL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs American Well Corp — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while American Well Corp trades at $8.8 (market cap $150.21M). The key difference: ADMA Biologics Inc is far larger — about 14.2× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AMWL | |
|---|---|---|
Market Cap | $2.13B | $150.21M |
Sector | Health | Health |
52-Week High | $20.38 | $9.83 |
52-Week Low | $7.60 | $3.78 |
Enterprise Value | $2.20B | -$25.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AMWL trades at $8.99, down 2.81% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows improving financial trends with revenue stabilizing near $249 million in 2025 and net losses narrowing to -$96 million. Recent news highlights momentum, including a Zacks upgrade to Buy on June 24, 2026, and Amazon appointing Amwell's co-founder to lead its healthcare unit on May 27, 2026.
Outlook remains cautious due to persistent losses and negative cash flow, though valuation metrics like P/S of 0.64 and P/B of 0.68 suggest potential upside if profitability improves. Risks include competitive pressures and execution challenges, but analyst consensus leans Hold with a $7.25 price target, indicating limited near-term growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →
